Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Lars Fruergaard Jørgensen betegnes af magasinet Fortune som den 29. mest magtfulde erhvervsleder i verden. Novo Nordisks ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

CEO Lars Fruergaard Jorgensen expressed concern, stating that only Novo Nordisk makes real semaglutide and does not supply it to others. “Honestly, I’m quite alarmed by what we see in the US ...

CEO Lars Fruergaard Jorgensen expressed concern, stating that only Novo Nordisk makes real semaglutide and does not supply it to others. “Honestly, I’m quite alarmed by what we see in the US ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

Lars Fruergaard Jørgensen, in a statement. The company’s diabetes and obesity care segment saw a 25% jump in sales, totaling DKK 191.8 billion. Within this, obesity care alone rose by an ...

Topchefen i Novo Nordisk, Lars Fruergaard Jørgensen, er tilfreds med udviklingen for Novo Nordisk i årets første ni måneder. Her har især salget af Ozempic og Wegovy drevet selskabets vækst.

Novo Nordisk earned 72.8 billion kroner in operating profit over the first nine months of 2024, an 18 percent increase from last year, according to its third-quarter report. Revenue rose to nearly 205 ...

For the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER. Growth reported in Danish kroner is now expected to be 1 ...

Novo Nordisk har tjent 72,8 milliarder kroner i årets første ni måneder. Det er 18 procent mere end i samme periode i 2023.